Close Menu

NEW YORK – Curetis and OpGen announced today that the two companies have entered into a definitive agreement to combine businesses.

The transaction will be structured as an acquisition by OpGen of Curetis GmbH, a subsidiary of Curetis that owns all of the Curetis Group business. Upon closing of the transaction, which is expected in early 2020, Curetis GMbH will become a wholly owned subsidiary of OpGen.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.

Dec
17
Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.